Citizen Science Finds New Endometriosis Comorbidities, But No Vaginal Microbiome Shift

Endometriosis affects roughly one in ten women of reproductive age, yet it takes an average of seven to ten years to diagnose, partly because the condition overlaps with so many other disorders in ways that remain poorly understood. A new study from the Isala citizen-science platform in Flanders, Belgium, set out to map those overlaps at scale while simultaneously testing a popular hypothesis: that women with endometriosis carry a distinctively different vaginal microbiome. The results, published in npj Women's Health, confirmed striking comorbidity patterns but found no meaningful shift in vaginal microbiome composition or diversity.

Significant Comorbidities Identified Across Endometriosis Patients

The Isala team, led by I. Rahou, T. Gehrmann, S. Ahannach, and CN Allonsius among others, analysed vaginal microbiome profiles collected through the citizen-science platform alongside self-reported health data from participants in Flanders. What emerged from the analysis was a set of significant associations between endometriosis and a range of comorbid conditions. The study did not release a full breakdown in the abstract, but the associations were described as statistically significant, pointing to a broader systemic picture of the disease rather than an isolated reproductive condition. Identifying which disorders cluster with endometriosis matters enormously for clinicians who often see patients cycling through specialists without a unifying framework.

Why These Comorbidity Patterns Matter for Diagnosis and Treatment

Endometriosis is already known to co-occur with conditions like irritable bowel syndrome, interstitial cystitis, and autoimmune disorders, but population-level data on the full comorbidity landscape have been scarce. When comorbidities are documented at scale, they give clinicians a clearer picture of what to look for and can shorten the diagnostic odyssey many patients endure. They also open questions about shared biological mechanisms, whether inflammation, immune dysregulation, or hormonal signalling drives multiple conditions simultaneously. NICHD endometriosis research programs have flagged exactly this kind of systems-level understanding as a priority for the field, making the Isala findings timely.

How the Isala Citizen-Science Platform Made Large-Scale Sampling Possible

The study's reach depended on the Isala platform's unusual design. Citizen science in public health research actively involves community members in formulating questions, collecting samples, and submitting health data, which allows researchers to assemble cohorts far larger than a typical clinical trial could recruit. Participants in Isala collected their own vaginal swabs at home and submitted them alongside detailed questionnaires, a method that reduces the clinical-setting bias that plagues many microbiome studies and recruits from a broader demographic cross-section. The result was a dataset with enough statistical power to detect associations that smaller studies would miss entirely.

Vaginal Microbiome Composition Shows No Significant Difference in Endometriosis

Perhaps the most counterintuitive finding is what the researchers did not find. Despite the clear comorbidity signal, the vaginal microbiome profiles of women with endometriosis did not differ significantly from those without the condition, either in community composition or in diversity measures. This is a meaningful null result. The hypothesis that endometriosis is accompanied by microbiome dysbiosis in the vaginal tract has circulated widely, fed partly by smaller studies with inconsistent results. A systematic scoping review on microbiome dysbiosis and endometriosis noted that existing human studies are often small, use varied methods, and show contradictory outcomes, with no clear endometriosis-specific microbiome signature emerging. The Isala study adds a larger, more rigorously collected dataset to that picture and arrives at the same sceptical conclusion for the vaginal niche specifically.

This does not close the question for every body compartment. Research on challenges in defining a healthy uterine microbiota highlights that the endometrial environment is harder to sample, more prone to contamination artefacts, and studied in far fewer participants. It remains possible that microbiome differences exist in the uterine cavity or the peritoneal fluid while the vaginal compartment stays stable. The Isala findings sharpen rather than settle the debate by narrowing where researchers should focus.

Open Questions About Endometriosis Mechanisms and Microbiome Research Scope

Several limitations are worth flagging. The study relied on self-reported diagnoses of endometriosis, which introduces the possibility that some participants were undiagnosed or misclassified, particularly given how long endometriosis typically takes to confirm. Self-collected swabs, while enabling scale, may also carry more variability than clinician-collected samples. The cohort is drawn entirely from Flanders, so how well findings generalise to other populations remains an open question. And the focus on vaginal microbiome profiles means the peritoneal, endometrial, and gut compartments, all of which have been proposed as more mechanistically relevant, were not assessed here.

The comorbidity associations themselves also require follow-up. Identifying that endometriosis clusters with other conditions is a first step; understanding the directionality and biology behind those links demands longitudinal data and mechanistic studies that cross-sectional citizen science cannot yet provide.

What Comes Next for Endometriosis and Microbiome Research

The Isala study's strongest contribution may be its demonstration that citizen-science platforms can generate hypothesis-testing datasets at a scale and speed that clinical recruitment cannot match. For endometriosis specifically, where patients are historically underserved by research funding and often dismissed during the diagnostic process, having a large community-driven dataset is itself a meaningful advance. Future work will likely turn toward the uterine and gut microbiomes, where the biological case for dysbiosis in endometriosis is somewhat stronger, and toward longitudinal designs that can track whether microbiome states change as the disease progresses or in response to treatment. The null result on vaginal microbiome is not a dead end; it is a redirect toward more productive territory.